Commentary On: Screening of Immunosuppressive Cells from Colorectal Adenocarcinoma and Identification of Prognostic Markers

Overview

Journal Biosci Rep

Specialty Cell Biology

Date 2021 Dec 1

PMID 34850851

Citations 3

Authors

Kexin Chen

Zhen Zeng

Chunxiang Ma

Yuan Dang

Hu Zhang

Affiliations

Soon will be listed here.

Abstract

Colorectal adenocarcinoma (COAD) is one subtype of colorectal carcinoma (CRC), whose development is associated with genetics, inappropriate immune response, and environmental factors. Although significant advances have been made in the treatment of COAD, the mortality rate remains high. It is a pressing need to explore novel therapeutic targets of COAD. Available evidence indicated that immune cell infiltration was correlated with cancer prognosis. To reveal the roles of immune cells in the COAD prognosis, a study published in Bioscience Reports by Li et al. (Bioscience Reports (2021) 41, https://doi.org/10.1042/BSR20203496) analyzed data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) dataset. It demonstrated a beneficial effect of Th17 cells in COAD prognosis. In addition, six hub genes (KRT23, ULBP2, ASRGL1, SERPINA1, SCIN, and SLC28A2) were identified to correlate with Th17 cells and COAD prognosis, suggesting one new therapy strategy and some predictive biomarkers of COAD. These findings reported by Li et al. may pave one way to explore the molecular mechanism of COAD further.

Citing Articles

[Procedures of complementary medicine in rheumatology].

Keysser G, Frohne I, Schultz O, Reuss-Borst M, Sander O, Pfeil A Z Rheumatol. 2024; 83(7):549-561.

PMID: 38935116 DOI: 10.1007/s00393-024-01524-9.

Identification and immunological characterization of cuproptosis-related molecular clusters in ulcerative colitis.

Pu Y, Meng X, Zou Z BMC Gastroenterol. 2023; 23(1):221.

PMID: 37370003 PMC: 10304604. DOI: 10.1186/s12876-023-02831-2.

IGF2BP2 maybe a novel prognostic biomarker in oral squamous cell carcinoma.

Wang X, Xu H, Zhou Z, Guo S, Chen R Biosci Rep. 2022; 42(2).

PMID: 35129592 PMC: 8859425. DOI: 10.1042/BSR20212119.

References

Zhou T, Wu L, Ma N, Tang F, Yu Z, Jiang Z . SOX9-activated FARSA-AS1 predetermines cell growth, stemness, and metastasis in colorectal cancer through upregulating FARSA and SOX9. Cell Death Dis. 2020; 11(12):1071. PMC: 7736271. DOI: 10.1038/s41419-020-03273-4. View

Sieminska I, Baran J . Myeloid-Derived Suppressor Cells in Colorectal Cancer. Front Immunol. 2020; 11:1526. PMC: 7426395. DOI: 10.3389/fimmu.2020.01526. View

Bardelli A, Siena S . Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 2010; 28(7):1254-61. DOI: 10.1200/JCO.2009.24.6116. View

Wu X, Gu Z, Chen Y, Chen B, Chen W, Weng L . Application of PD-1 Blockade in Cancer Immunotherapy. Comput Struct Biotechnol J. 2019; 17:661-674. PMC: 6558092. DOI: 10.1016/j.csbj.2019.03.006. View

Zhen Y, Luo C, Zhang H . Early detection of ulcerative colitis-associated colorectal cancer. Gastroenterol Rep (Oxf). 2018; 6(2):83-92. PMC: 5952942. DOI: 10.1093/gastro/goy010. View

De Simone V, Franze E, Ronchetti G, Colantoni A, Fantini M, Di Fusco D . Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. Oncogene. 2014; 34(27):3493-503. PMC: 4493653. DOI: 10.1038/onc.2014.286. View

Zhu G, Xu Y, Li J, Niu H, Ma W, Xu J . Mir20a/106a-WTX axis regulates RhoGDIa/CDC42 signaling and colon cancer progression. Nat Commun. 2019; 10(1):112. PMC: 6328557. DOI: 10.1038/s41467-018-07998-x. View

Li F, Zhou J, Li Z, Zhang L . Screening of immunosuppressive cells from colorectal adenocarcinoma and identification of prognostic markers. Biosci Rep. 2021; 41(4). PMC: 8024875. DOI: 10.1042/BSR20203496. View

Blum A, Wang P, Zenklusen J . SnapShot: TCGA-Analyzed Tumors. Cell. 2018; 173(2):530. DOI: 10.1016/j.cell.2018.03.059. View

10.

Xing C, Wang M, Ajibade A, Tan P, Fu C, Chen L . Microbiota regulate innate immune signaling and protective immunity against cancer. Cell Host Microbe. 2021; 29(6):959-974.e7. PMC: 8192480. DOI: 10.1016/j.chom.2021.03.016. View

11.

Peltier J, Roperch J, Audebert S, Borg J, Camoin L . Quantitative proteomic analysis exploring progression of colorectal cancer: Modulation of the serpin family. J Proteomics. 2016; 148:139-48. DOI: 10.1016/j.jprot.2016.07.031. View

12.

Jung G, Hernandez-Illan E, Moreira L, Balaguer F, Goel A . Epigenetics of colorectal cancer: biomarker and therapeutic potential. Nat Rev Gastroenterol Hepatol. 2020; 17(2):111-130. PMC: 7228650. DOI: 10.1038/s41575-019-0230-y. View

13.

Baldi S, Khamgan H, Qian Y, Wu H, Zhang Z, Zhang M . Downregulated ARID1A by miR-185 Is Associated With Poor Prognosis and Adverse Outcomes in Colon Adenocarcinoma. Front Oncol. 2021; 11:679334. PMC: 8367751. DOI: 10.3389/fonc.2021.679334. View

14.

Wang M, Yu L, Wei X, Wei Y . Role of tumor gene mutations in treatment response to immune checkpoint blockades. Precis Clin Med. 2022; 2(2):100-109. PMC: 8985804. DOI: 10.1093/pcmedi/pbz006. View

15.

Zhang N, Zhang R, Zou K, Yu W, Guo W, Gao Y . Keratin 23 promotes telomerase reverse transcriptase expression and human colorectal cancer growth. Cell Death Dis. 2017; 8(7):e2961. PMC: 5550880. DOI: 10.1038/cddis.2017.339. View

16.

Di J, Liu M, Fan Y, Gao P, Wang Z, Jiang B . Phenotype molding of T cells in colorectal cancer by single-cell analysis. Int J Cancer. 2020; 146(8):2281-2295. DOI: 10.1002/ijc.32856. View

17.

Ruan G, Wang S, Zhu L, Liao X, Wang X, Liao C . Investigation and verification of the clinical significance and perspective of natural killer group 2 member D ligands in colon adenocarcinoma. Aging (Albany NY). 2021; 13(9):12565-12586. PMC: 8148460. DOI: 10.18632/aging.202935. View

18.

Ganesh K, Stadler Z, Cercek A, Mendelsohn R, Shia J, Segal N . Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019; 16(6):361-375. PMC: 7295073. DOI: 10.1038/s41575-019-0126-x. View

19.

Tang Q, Chen J, Di Z, Yuan W, Zhou Z, Liu Z . TM4SF1 promotes EMT and cancer stemness via the Wnt/β-catenin/SOX2 pathway in colorectal cancer. J Exp Clin Cancer Res. 2020; 39(1):232. PMC: 7643364. DOI: 10.1186/s13046-020-01690-z. View

20.

Wang D, Yu W, Lian J, Wu Q, Liu S, Yang L . Th17 cells inhibit CD8 T cell migration by systematically downregulating CXCR3 expression via IL-17A/STAT3 in advanced-stage colorectal cancer patients. J Hematol Oncol. 2020; 13(1):68. PMC: 7275425. DOI: 10.1186/s13045-020-00897-z. View